Biotech News

HCW Biologics Secures up to $10.0 Million in Cash Through Debt Financing

HCW Biologics (HCWB)HCW BiologicsFinancing

Provides funding needed to complete HCW9302 Phase 1 study in alopecia areata and establish Recommended Phase 2 Dose Provides funding needed to complete HCW9302 Phase 1 study in alopecia areata and establish Recommended Phase 2 Dose

Related news

HCW Biologics

Fusion Immunotherapeutics HCW Biologics is a clinical-stage biopharmaceutical company developing fusion immunotherapeutics for autoimmune disease, cancer, and conditions associated with chronic inflammation and cellular senescence. Its pipeline is built around engineered cytokine and multispecific immune-cell engagement...

Recent company news

Stock data

Close
0.74 USD
Market cap
12.82M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States